Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNFA" or the "Company"), a clinical stage biopharmaceutical company committed to ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

Mounjaro is a GLP-1 inhibitor developed to help people with diabetes regulate their blood glucose. Elon Musk, the 53-year-old CEO of Tesla and SpaceX, recently shared a festive image of himself ...

Elon Musk/X Mounjaro, like Ozempic, is a GLP-1 inhibitor – a class of drugs developed to help people with diabetes regulate their blood glucose and insulin levels. However, Americans have ...

In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic ...

Not long after the FDA wrapped its preliminary investigation of GLP-1 receptor agonists and suicidal thoughts or actions, the ...

A lean-looking Elon Musk revealed Wednesday that he uses Mounjaro — after previously expressing support for similar weight-loss drugs as a means to curb America’s obesity epidemic. The ...

“There are reports of persons using GLP-1 inhibitors losing their interest in alcohol,” says Anne McTiernan, MD, PhD, an internist and epidemiologist at Fred Hutchinson Cancer Center in ...

Alongside the photo, Musk revealed that he uses Mounjaro, a GLP-1 inhibitor, instead of Ozempic, citing its fewer side effects and greater effectiveness In a festive spirit, Elon Musk, the 53-year ...

With the holidays past and the new year arrived, we look ahead — to losing weight. For some that resolve theoretically ...